Complex KT	Complex KT	NA	NA	NA	NA	NA	NA	NA	No	No	No	Complex KT	Structural aberration	AML	1A	NA	In the context of AML the presence of a complex genome (i.e. karyotype) in associated with an adverse prognosis (PMID: 35797463).
ABL1	chr9	130713043	130887675	+	Acute myeloid leukaemia with BCR::ABL1 fusion, (WHO, PMID: 35732831). B-lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1, B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features, B-lymphoblastic leukaemia/lymphoma, BCR-ABL1- like, B-lymphoblastic leukaemia/lymphoma with KMT2Arearrangement, (WHO, PMID: 35732831).	AML with t(9;22)(q34.1;q11.2)/BCR::ABL1ยง = 20%, (ICC, PMID: 35767897). B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1 (PMID: 36422706)	BCR	NA	No	Yes	Yes	Rearrangement/translocation	FUS	AML, ALL	1A if fused with BCR, otherwise 3A	NA	Optical Genome Mapping detected a translocation t(9;22)(q34.1;q11.2) with a variant allele frequency (VAF) of [%]. The t(9;22)(q34.1;q11.2) is a recurrent abnormality resulting in a BCR::ABL1 fusion. In the context of AML it is considered to have an adverse prognosis according to the ELN 2022 (PMID: 35797463).
SRSF2	chr17	76734115	76737333	-	Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897).	NA	NA	Core	Yes	Yes	Deletion/CN loss	LOF	AML	1A	NA	Mutated SRSF2 associated with adverse risk category (ELN, PMID: 35797463)
STAG2	chrX	123960212	124422664	+	Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831).	Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897).	NA	NA	Core	Yes	Yes	Deletion/CN loss	LOF	AML	1A	NA	Mutated STAG2 associated with adverse risk category (ELN, PMID: 35797463)
